AAV vectors vaccines against infectious diseases

Frontiers in Immunology

Volumn 5, Issue JAN, 2014, Pages

  Nieto, Karen ^a   Salvetti, Anna ^b,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

AAV vectors; Anti viral vaccination; Antibody gene transfer; Capsid; Cytotoxic responses; Humoral responses; Immunoadhesins

Indexed keywords

PARVOVIRUS VECTOR; VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; CD8+ T LYMPHOCYTE; CYTOTOXICITY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VIVO GENE TRANSFER; INFECTION; INFLUENZA VIRUS; NIPAH VIRUS; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TRANSGENE; VACCINATION; VIRUS CAPSID; WART VIRUS;

EID: 84895524123     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00005     Document Type: Review

References (73)

1. Liu MA. Immunologic basis of vaccine vectors. Immunity (2010) 33:504-15. doi: 10.1016/j.immuni.2010.10.004.
2. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol (2011) 23:377-82. doi:10.1016/j.coi.2011.03.006.
3. Manning WC, Paliard X, Zhou S, Bland MP, Lee AY, Hong K, et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoprotein B and D. J Virol (1997) 71:7960-2.
4. Flotte TR, Berns KI. Adeno-associated virus: a ubiquitous commensal of mammals. Hum Gene Ther (2005) 16:401-7. doi:10.1089/hum.2005.16.401.
5. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 12:341-55. doi:10.1038/nrg2988.
6. Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther (2013) 13:434-52.
7. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev (2008) 21:583-93. doi:10.1128/CMR.00008-08.
8. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther (2008) 16:1648-56. doi:10.1038/mt.2008.171.
9. Liu DW, Tsao YP, Kung JT, Ding YA, Sytwu HK, Xiao X, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol (2000) 74:2888-94. doi:10.1128/JVI.74.6.2888-2894.2000.
10. Liu DW, Chang JL, Tsao YP, Huang CW, Kuo SW, Chen SL. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. Int J Cancer (2005) 113:93-100. doi:10.1002/ijc.20530.
11. Kuck D, Lau T, Leuchs B, Kern A, Müller M, Gissman L, et al. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol (2006) 80:2621-30. doi:10.1128/JVI.80.6.2621-2630.2006.
12. Nieto K, Kern A, Leuchs B, Gissmann L, Muller M, Kleinschmidt JA. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antivir Ther (2009) 14:1125-37. doi:10.3851/IMP1469.
13. Zhou L, Zhu T, Ye X, Yang L, Wang B, Liang X, et al. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70. Hum Gene Ther (2010) 21:109-19. doi:10.1089/hum.2009.139.
14. Nieto K, Stahl-Hennig C, Leuchs B, Muller M, Gissmann L, Kleinschmidt JA. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther (2012) 23:733-41. doi:10.1089/hum.2011.202.
15. Xin KQ, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima H, et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum Gene Ther (2001) 12:1047-61. doi:10.1089/104303401750214276.
16. Xin KQ, Ooki T, Mizukami H, Hamajima K, Okudela K, Hashimoto K, et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther (2002) 13:1571-81. doi:10.1089/10430340260201662.
17. Xin KQ, Mizukami H, Urabe M, Toda Y, Shinoda K, Yoshida A, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol (2006) 80:11899-910. doi:10.1128/JVI.00890-06.
18. Lin J, Zhi Y, Mays L, Wilson JM. Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol (2007) 81:11840-9. doi:10.1128/JVI.01253-07.
19. Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J Clin Invest (2007) 117:3958-70. doi:10.1172/JCI33138.
20. Lin J, Calcedo R, Vandenberghe LH, Bell P, Somanathan S, Wilson JM. A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. J Virol (2009) 83:12738-50. doi:10.1128/JVI.01441-09.
21. Wu T, Topfer K, Lin SW, Li H, Bian A, Zhou XY, et al. Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther (2012) 20:572-9. doi:10.1038/mt.2011.280.
22. Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 79:955-65. doi:10.1128/JVI.79.2.955-965.2005.
23. Du L, He Y, Wang Y, Zhang H, Ma S, Wong CK, et al. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines. Virology (2006) 353:6-16. doi:10.1016/j.virol.2006.03.049.
24. Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL, Alexander IE. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine (2007) 25:1014-22. doi:10.1016/j.vaccine.2006.09.072.
25. Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R, et al. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine (2011) 29:1690-9. doi:10.1016/j.vaccine.2010.12.037.
26. Li X, Cao H, Wang Q, Di B, Wang M, Lu J, et al. Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice. Microbes Infect (2012) 14:1000-7. doi:10.1016/j.micinf.2012.05.002.
27. Rybniker J, Nowag A, Janicki H, Demant K, Hartmann P, Buning H. Incorporation of antigens into viral capsids augments immunogenicity of adeno-associated virus vector-based vaccines. J Virol (2012) 86:13800-4. doi:10.1128/JVI.01708-12.
28. Ploquin A, Szecsi J, Mathieu C, Guillaume V, Barateau V, Ong KC, et al. Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines. J Infect Dis (2013) 207:469-78. doi:10.1093/infdis/jis699.
29. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 14:316-27. doi:10.1016/j.ymthe.2006.05.009.
30. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine (2008) 26:1644-51. doi:10.1016/j.vaccine.2008.01.025.
31. Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci U S A (2006) 103:12993-8. doi:10.1073/pnas.0601433103.
32. Mays LE, Vandenberghe LH, Xiao R, Bell P, Nam HJ, Agbandje-Mckenna M, et al. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. J Immunol (2009) 182:6051-60. doi:10.4049/jimmunol.0803965.
33. Gao G, Wang Q, Calcedo R, Mays L, Bell P, Wang L, et al. Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther (2009) 20:930-42. doi:10.1089/hum.2009.060.
34. Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol (2002) 76:8769-75. doi:10.1128/JVI.76.17.8769-8775.2002.
35. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature (2012) 481:81-4. doi:10.1038/nature10660.
36. Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, et al. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology (2008) 378:79-85. doi:10.1016/j.virol.2008.04.016.
37. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 15:901-6. doi:10.1038/nm.1967.
38. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol (2013) 31:647-52. doi:10.1038/nbt.2618.
39. Limberis MP, Adam VS, Wong G, Gren J, Kobasa D, Ross TM, et al. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med (2013) 5:187ra172. doi:10.1126/scitranslmed.3006299.
40. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, Vanroey M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol (2005) 23:584-90. doi:10.1038/nbt1087.
41. De BP, Hackett NR, Crystal RG, Boyer JL. Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. Mol Ther (2008) 16:203-9. doi:10.1038/sj.mt.6300344.
42. Hicks MJ, Rosenberg JB, De BP, Pagovich OE, Young CN, Qiu JP, et al. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med (2012) 4:140ra187. doi:10.1126/scitranslmed.3003611.
43. Rosenberg JB, Hicks MJ, De BP, Pagovich O, Frenk E, Janda KD, et al. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior. Hum Gene Ther (2012) 23:451-9. doi:10.1089/hum.2011.178.
44. Mehendale S, Van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses (2008) 24:873-80. doi:10.1089/aid.2008.0292.
45. Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 4:23-35. doi:10.1038/nrmicro1323.
46. Wong KT. Emerging epidemic viral encephalitides with a special focus on henipaviruses. Acta Neuropathol (2010) 120:317-25. doi:10.1007/s00401-010-0720-z.
47. Williamson MM, Torres-Velez FJ. Henipavirus: a review of laboratory animal pathology. Vet Pathol (2010) 47:871-80. doi:10.1177/0300985810378648.
48. Lam SK. Nipah virus-a potential agent of bioterrorism? Antiviral Res (2003) 57:113-9. doi:10.1016/S0166-3542(02)00204-8.
49. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, et al. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 79:6690-702. doi:10.1128/JVI.79.11.6690-6702.2005.
50. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, et al. Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 80:12293-302. doi:10.1128/JVI.01619-06.
51. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, et al. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine (2008) 26:3842-52. doi:10.1016/j.vaccine.2008.05.016.
52. Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine (2011) 29:5623-30. doi:10.1016/j.vaccine.2011.06.015.
53. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, Lacasse R, et al. A Hendra virus g glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. Sci Transl Med (2012) 4:146ra107. doi:10.1126/scitranslmed.3004241.
54. Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME. Translational research insights from completed HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2013) 63(Suppl 2):S150-4. doi:10.1097/QAI.0b013e31829a3985.
55. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 372:1881-93. doi:10.1016/S0140-6736(08)61591-3.
56. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 102:325-39. doi:10.1093/jnci/djp534.
57. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet (2011) 377:2085-92. doi:10.1016/S0140-6736(11)60551-5.
58. Lehtinen M. Cross-protection is crucial for prophylactic HPV vaccination. Lancet Infect Dis (2012) 12:742-3. doi:10.1016/S1473-3099(12)70203-7.
59. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine (2012) 30(Suppl 5):F139-48. doi:10.1016/j.vaccine.2012.05.039.
60. Nieto K, Gissmann L, Schadlich L. Human papillomavirus-specific immune therapy: failure and hope. Antivir Ther (2010) 15:951-7. doi:10.3851/IMP1665.
61. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (2011) 378:1917-30. doi:10.1016/S0140-6736(11)61051-9.
62. Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A, Herzog RW. Innate immune responses to AAV vectors. Front Microbiol (2011) 2:194. doi:10.3389/fmicb.2011.00194.
63. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood (2011) 117:6459-68. doi:10.1182/blood-2010-10-314518.
64. Bartel MA, Weinstein JR, Schaffer DV. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Gene Ther (2012) 19:694-700. doi:10.1038/gt.2012.20.
65. Mays LE, Wang L, Tenney R, Bell P, Nam HJ, Lin J, et al. Mapping the structural determinants responsible for enhanced T cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33. J Virol (2013) 87:9473-85. doi:10.1128/JVI.00596-13.
66. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A (2002) 99:10405-10. doi:10.1073/pnas.162250899.
67. Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. Recent developments in adeno-associated virus vector technology. J Gene Med (2008) 10:717-33. doi:10.1002/jgm.1205.
68. Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, et al. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 7:e39741. doi:10.1371/journal.pone.0039741.
69. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis (2009) 199:381-90. doi:10.1086/595830.
70. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther (2010) 21:704-12. doi:10.1089/hum.2009.182.
71. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, et al. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol (2012) 188:6418-24. doi:10.4049/jimmunol.1200620.
72. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol (2013) 4:341. doi:10.3389/fimmu.2013.00341.
73. Maersch S, Huber A, Buning H, Hallek M, Perabo L. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology (2010) 397:167-75. doi:10.1016/j.virol.2009.10.021.